Close Menu
Coin USP.

    Subscribe to Updates

    Get the latest creative news from Coin USP about Crypto.

    What's Hot

    Kraken Parent’s Profit Rebound Still Leaves a Wide Gap Before Its IPO

    November 15, 2026

    AMD Just Had Its Biggest Run Against Nvidia Since 1999. Can It Survive Earnings?

    November 14, 2026

    Charles Hoskinson Clashes With Angry ADA Holders Over Promises of Price Gains

    November 14, 2026
    Facebook X (Twitter) Instagram
    Coin USP.
    • Blockchain
    • Crypto
    • Lite Coin
    • Tren&d
    • Press Release
    Coin USP.
    Home » Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now
    China News

    Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now

    Grace EvansBy Grace EvansOctober 7, 2026No Comments2 Mins Read
    Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Big pharma is sourcing assets from China biotech as $440 billion of drugs lose patents through 2032, Goldman Sachs says. Salveen Richter, the bank’s lead US biotech analyst, says Chinese rivals could shorten product cycles at Western drugmakers.

    Yet China’s five-year pharma plan, published Sept. 18, targets at least 25% of global first-in-class drugs by 2030. Those are medicines that work through a new mechanism rather than improving an existing drug.

    Is China Biotech a Supplier or a Rival for Big Pharma?

    AstraZeneca agreed last week to invest $2 billion in US-listed Summit Therapeutics. Summit licenses its lead cancer drug from China’s Akeso.

    Overseas licensing deals for Chinese drugs have reached more than $120 billion in total value this year, Xinhua reported. That is up 36% from a year earlier.

    Richter, however, told CNBC that most Chinese work still builds better versions of existing drugs, which could flood the market.

    Meanwhile, she says Chinese developers are aiming for a foothold in obesity, the market behind Eli Lilly’s stock rally.

    Richter says acquirers could pay smaller premiums over market value for biotechs outside China.

    “I do think that best-in-class first-in-class innovation around the world will still get rewarded.”

    Salveen Richter, lead US biotech analyst at Goldman Sachs, speaking to CNBC

    Will China’s Drug Data Hold Up in Western Patients?

    Richter points to Summit’s HARMONi-3 lung cancer trial against Merck’s cancer drug Keytruda. She says it will test whether Chinese data holds in Western patients.

    Summit expects the next data from squamous tumors, a lung cancer subtype, in the second half of 2026.

    An April interim analysis delivered no early win, and Summit shares opened 24% lower the next day.

    Richter says Chinese drugmakers already partnered with Western firms may become the next multinationals. She would follow them as biotech investment opportunities.

    Historically a supplier of drug ingredients, China now describes its industry as shifting toward exporting new medicines. Under the plan, 50 pharmaceutical companies would top 10 billion yuan ($1.5 billion) in annual revenue by 2030, Xinhua reported.

    Related Posts

    AMD Just Had Its Biggest Run Against Nvidia Since 1999. Can It Survive Earnings?

    November 14, 2026

    Big Banks Have Nearly $1 Trillion Tied to AI. What If the Boom Cracks?

    November 14, 2026

    Metaplanet Cuts 2026 Revenue Target 59%: Is the Bitcoin Playbook Running Dry?

    November 14, 2026

    Can Elon Musk Bring Jensen Huang Back as Nvidia CEO?

    November 14, 2026

    US Shuts Down All Flights, Stock Market Faces Major Risk

    November 13, 2026

    Bitcoin Miners Lead Wall Street’s Crypto Sell-Off: Why Are They Falling Hardest?

    November 13, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Don't Miss
    Businesses

    Kraken Parent’s Profit Rebound Still Leaves a Wide Gap Before Its IPO

    November 15, 2026

    Kraken parent Payward said clients kept adding assets for 12 straight months, even as those holdings lost dollar value. Its adjusted earnings rose to $60 million in the third quarter, up from $23 million in the second. However, that was still 67% below a year earlier, Bloomberg reported, citing a shareholder letter. These are its…

    AMD Just Had Its Biggest Run Against Nvidia Since 1999. Can It Survive Earnings?

    November 14, 2026

    Charles Hoskinson Clashes With Angry ADA Holders Over Promises of Price Gains

    November 14, 2026

    House Memo Targets Officials’ Prediction Market Bets

    November 14, 2026
    Our Picks

    Subscribe to Updates

    Leading platform dedicated to bringing you the latest updates, expert insights, and in-depth analysis from the world of cryptocurrencies, blockchain, and Web3. Our mission is to empower individuals and businesses with accurate information, helping them navigate the evolving digital finance landscape. Whether you're a beginner or a seasoned investor, we provide reliable news, market trends, and educational resources to keep you ahead in the crypto space. 🚀

    Facebook X (Twitter) Instagram
    • Blockchain
    • Crypto
    • Lite Coin
    • Tren&d
    • Press Release
    © 2026 Coin USP . . Designed by Coin.
    • Home
    • About Us
    • Contact Us
    • Privacy Policy​
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.